Introduction
Neurogen is a drug discovery and development company founded in 1987. The company established its presence in the pharmaceutical market by partnering with Pfizer and American Home Products in 1999. In addition, the company's proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), is the result of a successful collaboration with Merck for VR-1 research programs.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Neurogen is focused on developing small molecule drugs for disorders with unmet medical need, including insomnia, pain, obesity, depression and inflammation. The company utilizes its proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), for discovering and optimizing potential drug leads. The key elements of the company's business strategy include: advancing clinical development of its product candidates, acquiring potential product candidates through licensing agreements and continue to maximize the success of VR-1 research program with Merck. The company's total revenues declined at a CAGR of 11.1% during 2002-2006, from $15.7 million to $9.8 million. This represents an absolute total decline of -$5.9 million for total revenues. The decline is primarily due to the termination of the company's research collaboration with Aventis in September 2004.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
